Clinical research
AbbVie announced that its Phase III induction study, U-ACHIEVE, of Rinvoq (upadacitinib) in moderate to severe ulcerative colitis, hit the primary endpoint of clinical remission at week 8.
The COVID-19 vaccine under development by China’s Sinopharm is showing efficacy of 86%, health authorities from the United Arab Emirates reported this morning.
AstraZeneca and the University of Oxford published an interim analysis of their four Phase III clinical trials of AZD1222, their COVID-19 vaccine.
Constellation Pharmaceuticals announced on Sunday that it has received preliminary data from its Phase II MANIFEST and Phase III MANIFEST-2 clinical trials involving CPI-0610 for myelofibrosis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
As the dose of Sutro Biopharma’s ovarian cancer drug, STRO-002, increased in an ongoing Phase I dose-escalation trial, survival rates have also increased.
Like the Grinch’s heart at Christmas, the Nasdaq Exchange grew a little bigger this week with multiple life science companies raising hundreds of millions of dollars in initial public offerings.
A dual treatment approach consisting of gemcitabine combined with AB Science’s masitinib was associated with significant increases in survival among patients with pancreatic cancer and pain.
The four promising treatments showed no effect on reducing mortality in ongoing Solidarity Trial.
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
PRESS RELEASES